- Merrimack Receives $225 Million Milestone Payment from Ipsen
- Merrimack Reports Full Year 2023 Financial Results
- Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
Key statistics
On Thursday, Merrimack Pharmaceuticals Inc (MACK:NMQ) closed at 14.73, -7.30% below its 52-week high of 15.89, set on Feb 13, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 14.71 |
---|---|
High | 14.75 |
Low | 14.70 |
Bid | 14.70 |
Offer | 14.77 |
Previous close | 14.71 |
Average volume | 100.88k |
---|---|
Shares outstanding | 14.53m |
Free float | 14.36m |
P/E (TTM) | -- |
Market cap | 214.05m USD |
EPS (TTM) | -0.0826 USD |
Data delayed at least 15 minutes, as of Apr 25 2024 21:00 BST.
More ▼